The latest London South East Webinar takes place on July 6. Come and hear CEO’s from Orosur Mining, Caledonia Mining, Glantus Holdings and Tekcapital speak. Please register here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmryt Pharma Share News (AMYT)

Share Price Information for Amryt Pharma (AMYT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 167.50
Bid: 165.00
Ask: 170.00
Change: 0.00 (0.00%)
Spread: 5.00 (3.03%)
Open: 167.50
High: 167.50
Low: 165.00
Prev. Close: 167.50
AMYT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

European approval for Amryt's Oleogel-S10 moves closer

Mon, 29th Mar 2021 09:15

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the validation of its marketing authorisation application for 'Oleogel-S10' by the European Medicines Agency on Monday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa.
The AIM-traded firm described epidermolysis bullosa (EB) as a "rare and distressing" genetic skin disorder affecting young children and adults, for which there was currently no approved treatment.

It said the European Medicines Agency (EMA) validation confirmed that the application was sufficiently complete to begin the formal review process.

The EMA review for Oleogel-S10 would be according to standard timelines, with an opinion of the Committee for Medicinal Products for Human Use (CHMP) expected within 210 'active' days, which excludes any pauses for the applicant to provide answers to questions from the committee.

Amryt said the marketing authorisation application (MAA) was supported by data from the EASE pivotal phase 3 trial in EB.

It announced in October that the EASE study met its primary endpoint of accelerated healing of the target wound by day 45 in patients treated with Oleogel-S10, when compared to the control gel.

"The validation of the Oleogel-S10 MAA marks another important milestone for Amryt as we progress our lead development candidate Oleogel-S10 with the regulatory authorities in both Europe and the US," said chief executive officer Dr Joe Wiley.

"Today's news also represents a potentially important advancement for patients and families living with this rare and distressing disorder.

"We will continue to work closely with the respective regulatory authorities with the hope of bringing Oleogel-S10 to patients as soon as possible."

At 0813 GMT, shares in Amryt Pharma were up 2.5% at 205p.

More News

Cathal Friel-led Poolbeg Pharma set to float on AIM

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.

17 Jun 21 14:34

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

3 Jun 21 19:20

FDA grants Amryt's Oleogel-S10 priority review status

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).

3 Jun 21 11:26

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

2 Jun 21 19:10

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

5 May 21 19:20

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

6 Apr 21 14:54

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

31 Mar 21 11:50

Amryt releases data from Italy lomitapide study

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma released efficacy and safety data from the 'Lochnes' investigator-sponsored study of lomitapide in familial chylomicronemia syndrome (FCS) on Tuesday, which was conducted by expert lipidologists in Italy.

30 Mar 21 12:11

European approval for Amryt's Oleogel-S10 moves closer

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced the validation of its marketing authorisation application for 'Oleogel-S10' by the European Medicines Agency on Monday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa.

29 Mar 21 09:15

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

IN BRIEF: Amryt gets positive feedback on Myalept from US regulator

23 Mar 21 19:03

Amryt upbeat on positive FDA feedback

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma has received further feedback from the United States Food and Drug Administration (FDA) on Myalept, it said on Tuesday, and its proposed development plan and study design to support an indication for patients with partial lipodystrophy (PL).

23 Mar 21 09:34

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

IN BRIEF: Amryt's Myalepta secures reimbursement approval in France

22 Mar 21 19:07

Amryt's Myalepta gets reimbursement approval in France

(Sharecast News) - Commercial-stage biopharmaceuticals company Amryt Pharma announced on Monday that the French Ministry of Social Affairs and Health has approved 'Myalepta', or metreleptin, for reimbursement in the country as an adjunct to diet as replacement therapy.

22 Mar 21 09:04

Director dealings: Amryt Pharma chairman makes share purchase

(Sharecast News) - Amryt Pharma revealed on Monday that chairman Ram Stafford had acquired 300,100 ordinary shares in the AIM-listed commercial-stage biopharmaceutical company.

15 Mar 21 16:38

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

IN BRIEF: Amryt, Medison sign distribution deal for Myalepta in Canada

9 Mar 21 06:55

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.